Skip to main content
. 2016 Jan 27;2016:3439707. doi: 10.1155/2016/3439707

Table 1.

Emetogenic Potential of Chemotherapeutic Agents.

Level Agent
High emetic risk (>90% frequency of emesis) (i) AC combination defined as either doxorubicin or epirubicin with cyclophosphamide 
(ii) Carmustine >250 mg/m2 
(iii) Cisplatin ≥50 mg/m2 
(iv) Cyclophosphamide >1500 mg/m2 
(v) Dacarbazine 
(vi) Doxorubicin > 60 mg/m2 
(vii) Epirubicin >90 mg/m2 
(viii) Ifosfamide ≥ 10 g/m2 
(ix) Mechlorethamine 
(x) Streptozocin
Moderate emetic risk (30%–90% frequency of emesis) (i) Aldesleukin > 12–15 million international units/m2 
(ii) Amifostine > 300 mg/m2 
(iii) Arsenic trioxide 
(iv) Azacitidine 
(v) Bendamustine 
(vi) Busulfan 
(vii) Carboplatin 
(viii) Carmustine ≤ 250 mg/m2 
(ix) Cisplatin < 50 mg/m2 
(x) Clofarabine 
(xi) Cyclophosphamide ≤ 1500 mg/m2 
(xii) Cytarabine >200 mg/m2 
(xiii) Dactinomycin 
(xiv) Daunorubicin  
(xv) Doxorubicin ≤ 60 mg/m2 
(xvi) Epirubicin ≤ 90 mg/m2 
(xvii) Idarubicin 
(xviii) Ifosfamide < 10 g/m2 
(xix) Interferon alfa ≥ 10 million international units/m2 
(xx) Irinotecan 
(xxi) Melphalan 
(xxii) Methotrexate ≥ 250 mg/m2 
(xxiii) Oxaliplatin 
(xxiv) Temozolomide